Tourmaline Oil Corp. closed 5.4% below its 52-week high of C$70.83, which the company achieved on February 21st.

Tourmaline Oil Corp. closed 6.6% below its 52-week high of C$70.83, which the company achieved on February 21st.

Tourmaline Capital Partners paid $76 million for the Columbus Center office complex in Coral Gables, which was facing ...

The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular med Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings.

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have received a consensus recommendation of “Buy” from the ...

Desjardins analyst Gary Ho downgraded Tourmaline Oil (TOU – Research Report) to a Hold today and set a price target of C$74.00. The company’s ...

In December 2024, Tourmaline announced the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...